The world's first!

Article source: Medical Cube Info

Author: Pickup

On January 20, the drug clinical trial registration and information publicity platform showed that Hengrui Medicine registered the phase I clinical study of CD112R/TIGIT dual anti-SHR-2002, aiming to evaluate the candidate drug alone or in combination with other anti-tumor treatments in the late stage.
Safety, tolerability, pharmacokinetics, and efficacy in patients with malignancy
.

SHR-2002 is a dual antibody against the new target CD112R/TIGIT independently developed by Hengrui Medicine and the world's first.
It is the first drug of the same type in the world to enter clinical development
.

According to the Clinical Trials.
gov website, Hengrui Medicine has registered a phase I clinical study of SHR-2002 combined with PDL1 adebelimumab in the treatment of advanced malignant tumors in October last year, and the study will recruit 50 patients
.

Adbelimumab is a PDL1 monoclonal antibody independently developed by Hengrui.
It has just submitted a marketing application in China yesterday.
It is used in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer
.

PVRIG, a novel immune checkpoint on the TIGIT/DNAM axis, is expressed on NK and CD8+ T cells in a variety of cancers
.

At present, the world's fastest-growing anti-PVRIG mAb is COM701 from Compugen.

It is worth noting that Junshi Bio has also deployed anti-PVRIG monoclonal antibodies and CD112R/TIGIT dual antibodies, which are currently in the preclinical stage

Note: The original text has been deleted